<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478957</url>
  </required_header>
  <id_info>
    <org_study_id>PA101-SM-02</org_study_id>
    <nct_id>NCT02478957</nct_id>
  </id_info>
  <brief_title>Treatment of Indolent Systemic Mastocytosis With PA101</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patara Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Patara Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in&#xD;
      adult patients with indolent systemic mastocytosis (ISM).&#xD;
&#xD;
      The purpose of the study is to determine the efficacy and safety profile of PA101 delivered&#xD;
      via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using&#xD;
      standard treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The symptom scores for determining eligibility will be established during the 2-week Run-in&#xD;
      Period using eDiary and the eligible patients will be randomly allocated in a 2:1 ratio to&#xD;
      one of two treatment cohorts at the baseline visit.&#xD;
&#xD;
      In Cohort 1 (n=24), patients will receive inhaled 40 mg PA101 three times daily and inhaled&#xD;
      placebo three times daily via eFlow for 6 weeks each in a double-blind, 2-period crossover&#xD;
      fashion with a 4-week washout period between the treatment periods.&#xD;
&#xD;
      In Cohort 2 (n=12), patients will receive inhaled 40 mg PA101 three times daily via eFlow and&#xD;
      oral cromolyn sodium 200 mg four times daily for 6 weeks each in an open label, 2-period&#xD;
      crossover fashion with a 4-week washout period between the treatment periods.&#xD;
&#xD;
      Patients will be allowed to use the same daily doses of pre-randomization H1 and H2&#xD;
      antihistamines as well as the same daily doses of any other allowed medications during each&#xD;
      treatment period.&#xD;
&#xD;
      Visits during each treatment period will occur at the baseline Visit, and at the end of Weeks&#xD;
      1, 2, 4, and 6.&#xD;
&#xD;
      Blood and urine samples will be collected to test for various biomarkers. In a subset of&#xD;
      patients, additional clinical assessments of the skin will be performed and blood samples&#xD;
      will be collected for pharmacokinetic assessments. Clinical safety assessments will be&#xD;
      performed in all patients at the start and end of each treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall symptom score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mastocytosis Activity of Symptoms (MAS Plus) questionnaire for daily symptom score using eDiary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease specific quality of life (QoL)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mastocytosis Impact Questionnaire (MIQ) for quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Mastocytosis</condition>
  <condition>Systemic Mastocytosis</condition>
  <condition>Indolent Systemic Mastocytosis</condition>
  <arm_group>
    <arm_group_label>PA101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PA101, 40 mg administered via inhalation three times daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, administered via inhalation three times daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PA101</intervention_name>
    <description>40 mg PA101 administered via inhalation three times daily for 6 weeks</description>
    <arm_group_label>PA101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo administered via inhalation three times daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of indolent systemic mastocytosis (ISM) according to the WHO criteria and&#xD;
             the consensus proposal (2001)&#xD;
&#xD;
          -  Experiencing at least one predefined qualifying symptom in at least two organ systems&#xD;
             within 3 months of Screening despite the use of H1 and/or H2 antihistamines and other&#xD;
             anti-mediator therapy&#xD;
&#xD;
          -  Experiencing symptoms with a severity score of at least 4 for at least 7 out of 14&#xD;
             days during the Run-in period with at least one predefined qualifying symptom each&#xD;
             from at least two organ systems, despite the use of H1 and/or H2 antihistamines and/or&#xD;
             other anti-mediator therapy&#xD;
&#xD;
          -  Willing and able to use an eDiary device daily for the duration of the study&#xD;
&#xD;
          -  Completed at least 5 eDiary reports during each of two consecutive weeks of the Run-in&#xD;
             period&#xD;
&#xD;
          -  Willing and able to provide written informed consent prior to any study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced systemic mastocytosis (i.e., aggressive systemic mastocytosis [ASM], mast&#xD;
             cell leukemia [MCL], or systemic mastocytosis with an associated clonal hematologic&#xD;
             non-mast cell lineage disease [SM-AHNMD] )&#xD;
&#xD;
          -  Current or recent history of clinically significant cardiovascular, hematological,&#xD;
             renal, neurologic, hepatic, endocrine, psychiatric, malignant, or other illnesses that&#xD;
             could put the patient at risk or compromise the quality of the study data as&#xD;
             determined by the Investigator&#xD;
&#xD;
          -  Use of oral cromolyn sodium within 6 weeks of Screening&#xD;
&#xD;
          -  History of systemic corticosteroid, immunosuppressive, or anti-IgE monoclonal antibody&#xD;
             therapy (e.g., omalizumab) within 6 months of Screening&#xD;
&#xD;
          -  History of anaphylaxis requiring systemic treatment (i.e., corticosteroid or&#xD;
             epinephrine) within 12 months of Screening&#xD;
&#xD;
          -  Upper or lower respiratory tract infection within 4 weeks of Screening&#xD;
&#xD;
          -  History of malignancy within the last 5 years, except basal cell carcinoma or cervix&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  Major surgery within 6 months of Screening&#xD;
&#xD;
          -  Current or recent history (within 12 months) of excessive use or abuse of alcohol&#xD;
&#xD;
          -  Current or recent history (within 12 months) of abusing legal drugs or use of illegal&#xD;
             drugs or substances&#xD;
&#xD;
          -  Pregnant or breastfeeding females, or if of child-bearing potential unwilling to&#xD;
             practice acceptable means of birth control or abstinence during the study&#xD;
&#xD;
          -  Participation in any other investigational drug study within 4 weeks of Screening&#xD;
&#xD;
          -  History of hypersensitivity or intolerance to aerosol medications or cromolyn sodium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Siebenhaar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technical University München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Salerno</name>
      <address>
        <city>Salerno</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 19, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastocytosis</keyword>
  <keyword>cromolyn sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

